BLA submitted to FDA for pivekimab sunirine in BPDCN
A new Biologics License Application (BLA) has been submitted to the US Food and Drug Administration (FDA) for approval of the investigational therapy
Leukemia
Acute Myeloid Leukemia
Lymphoma News
SOHO 2025
Meetings / Conferences
Video Interviews
Dr. Kantarjian interviews Dr. Graff on MorningSun trial at SOHO 2025
The trial, which investigated the efficacy and safety of frontline subcutaneous mosunetuzumab, a CD20/CD30-directed bispecific antibody, was part of the MorningSun basket trial.
Leukemia
Acute Lymphoblastic Leukemia
Free patient resource aims to guide those with difficult diagnoses
Bev Lewyn was 48 years old when her life was upended by two blows in quick succession. In 2015 she was diagnosed with
Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
News
Anthony G. Letai, MD, PhD, sworn in as NCI Director
Anthony G. Letai, MD, PhD, was sworn in on September 29, 2025, as director of the National Cancer Institute (NCI), part of the
Leukemia
Acute Lymphoblastic Leukemia
FDA authorizes new companion diagnostic for KMTA-rearranged acute leukemia
The US Food and Drug Administration (FDA) has granted a De Novo Classification Request for the CytoCell KMT2A Breakapart FISH Probe Kit PDx,
MPN News
SOHO 2025
Dr. Cheema discusses SOHO 2025 abstract on PV, GLP-1a therapy
In this video interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Asfand Yar Cheema, MD, resident physician
2025 IMS
Multiple Myeloma
Linvoseltamab shows strong 1st results in high-risk smoldering myeloma
The study was led by Paula Rodríguez-Otero, MD, PhD, a consultant hematologist at Clínica Universidad de Navarra, on September 19, 2025, who presented
2025 IMS
Interim analysis shows promise in belantamab-based maintenance in high-risk MM
In patients with high-risk multiple myeloma, maintenance therapy with belantamab, pomalidomide, and dexamethasone (BPD) demonstrated encouraging activity and a manageable safety profile, according
2025 IMS
Multiple Myeloma
Daratumumab raises early infection risk in myeloma
Daratumumab raises early infection risks in patients treated with multiple myeloma, according to an oral abstract presented on September 17, 2025, at the
Lymphoma News
SOHO 2025
Cellular Therapy
News
Video Interviews
Dr. Karmali discusses phase 2 TRANSCEND FL study results
In this video interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Reem Karmali, MD, an associate professor